 DS-8201a,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crc01', 'breast']
impressive data on tdxd improving pfs and os in her2-low breast cancer + standing ovation at #asco22 with deafening applause! no responses in her2-low mcrc in destiny-crc01. why? thoughts? 
Medical Oncologist, GI cancers @nki_nl neoadjuvant #immunotherapy #cancerresearch. Opinions my own